Publication | Open Access

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques

VaccinationVaccine DevelopmentTier-2 Hiv-1-neutralizing AntibodiesHuman RetrovirusImmunologyAntiviral ResponseVirologyHumoral ImmunityVaccine DesignHivMedicineViral ImmunityHeterologous Shiv Infection